Gilead Sciences Inc. (GILD) News
Filter GILD News Items
GILD News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
GILD News Highlights
- GILD's 30 day story count now stands at 74.
- Over the past 24 days, the trend for GILD's stories per day has been choppy and unclear. It has oscillated between 1 and 16.
- The most mentioned tickers in articles about GILD are DRUG, RAIN and MG.
Latest GILD News From Around the Web
Below are the latest news stories about Gilead Sciences Inc that investors may wish to consider to help them evaluate GILD as an investment opportunity.
3 Moonshot Stocks Insiders Are Buying. What Do They Know?Biotech stocks aren't a sure thing, but one good sign is insiders buying up shares. |
VIR Q4 Earnings Beat on Higher Revenues From Covid TreatmentVIR beat earnings estimates in the fourth quarter on higher sotrovimab revenues for COVID-19 patients. |
Gilead Launches Pharmaceutical Education Program to Increase Workplace Diversity (Black Enterprise)By Derek Major |
Tesla Is Just One Reason Why Stocks Are Actually 21% Cheaper NowCurious just how much cheaper the S&P 500 is now due to the sell-off? It's now a nearly a quarter off in about a year's time. |
Is Moderna the Next Gilead or the Next Regeneron?MRNA stock is seen purely as a Covid-19 play. |
Understanding Hepatitis D: 4 Questions With Professor Maria ButiMost people are familiar with the hepatitis B (HBV) and hepatitis C (HCV) viruses that attack the liver. But not many have heard of hepatitis D (HDV), the most severe form of viral hepatitis. Peopl... |
Toll-Like Receptor Agonist Pipeline Insights | Research Report 2022 by DelveInsightLas Vegas, USA, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Toll-Like Receptor Agonist Pipeline Insights | Research Report 2022 by DelveInsight Toll-Like Receptor Agonist Pipeline constitutes 45+ key companies continuously working towards developing 45+ Toll-Like Receptor Agonist treatment therapies, analyzes DelveInsight DelveInsight''s Toll-Like Receptor Agonist Pipeline Insight 2022'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Toll-Like Receptor Agonist pipeline domain. Some of the essential takeaways from the Toll-Like Receptor Agonist Pipeline report: DelveInsight''s Toll-Like Receptor (TLR) Agonist... |
Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To US$0.73Gilead Sciences, Inc. ( NASDAQ:GILD ) will increase its dividend on the 30th of March to US$0.73. This takes the... |
Want To Collect $200 Every Month? Invest $49,334 in These 3 StocksYou don't need to invest in stocks that pay monthly just to collect a recurring dividend income each month. |
Charting a Career to Help Reduce Health Inequity: Porscha's StoryDr. Porscha Showers’ route to health sciences wasn’t always a sure thing. Porscha, who grew up in Louisiana, wanted to become an attorney – despite having a mother who worked as a registered nurse ... |